With the rapid growth of artificial ielligence (AI) and machine learning (ML) technologies in the field of medical devices and digital health software, regulatory bodies are trying to develop appropriate standards and regulations to ensure the safety and efficiency of these technologies. In this regard, the United States, Europe, and the United Kingdom have approved and proposed various principles and guidelines for artificial ielligence-based devices independely as well as in the form of iernational cooperation.
Legal challenges of artificial ielligence based devices
In rece years, the use of artificial ielligence and machine learning in medical devices and digital health software has increased dramatically. By analyzing and learning from vast data, these technologies can improve disease diagnosis and provide more accurate medical recommendations. But determining which types of these programs require licensing and which types do not fall under medical laws has been a major challenge for regulatory bodies. Among the importa issues in this field are borderline programs; Applications that require monitoring due to their application in health, but are not recognized as medical devices.
Approval and licensing status of artificial ielligence based devices
Currely, the FDA has approved more than 700 artificial ielligence-based devices in the United States. This high number indicates that the legal path to approval of these devices has gradually become easier, although the field of medical imaging still accous for the largest share of these devices.
Predefined corol programs and possible changes
The FDA in America recely issued a guideline under the title Predefined change corol programs (PCCP) has published These programs allow companies to impleme specific changes without having to file a new application, which speeds up the process of evaluating and updating devices. Similar programs are being implemeed in the United Kingdom and Canada, which shows the common approach of these couries in monitoring new technologies.
Life cycle manageme and coinuous performance evaluation
One of the new ways to reduce the risk of artificial ielligence-based devices is to impleme post-launch performance manageme programs. These programs require manufacturers to test product performance in real-world environmes after release. Coinuous performance monitoring allows manufacturers to receive environmeal feedback, become aware of the poteial real-world impacts and risks of their devices, and make the necessary changes.
Looking to the future: Challenges and opportunities ahead
Due to the spread of adaptive artificial ielligence and automatic learning technologies, the need for more comprehensive regulations is felt. Also, issues such as the use of high quality data and the need to respect paties’ privacy will be importa challenges in this field.
